It is not possible to establish a single dosage regimen for theophylline or its derivatives (for example, aminophylline) that will suit all patients because the metabolism of theophylline varies greatly from person to person. This variation is reflected in its elimination half life, which varies from four hours in healthy adult smokers to about 25 hours in patients with hepatic cirrhosis.
It is not possible to establish a single dosage regimen for theophylline or its derivatives (for example, aminophylline) that will suit all patients because the metabolism of theophylline varies greatly from person to person. This variation is reflected in its elimination half life, which varies from four hours in healthy adult smokers to about 25 hours in patients with hepatic cirrhosis.
Several of the factors responsible for the variation (age, smoking habits, body weight, diet, concomitant illness, and drug interactions) can be considered when estimating the most appropriate dosage regimen. But the therapeutic:toxic ratio for theophylline is very small, and only by measuring the plasma theophylline concentration can the dosage be tailored for individual patients.
In this article we apply to theophylline the criteria that must be fulfilled in part or in full before the measurement of its plasma concentration can be considered worth while.
Criteria for measurement
The therapeutic effect of theophylline (shown as thi change in FEV1) increased with increasing plasma concentration in six patients with asthma.
Is there difficulty in interpreting clinical evidence ofthe therapeutic or toxic effects?
There is a relation between the dose of theophylline and the reduction in airways resistance achieved. The drug's chief therapeutic effect, however, is the relief of bronchoconstriction, which is only one of the three factors that cause airways obstruction in asthma, the other two being mucosal oedema and mucus plugging of the airways. Thus in asthmatic patients a change in FEVy, which reflects all three factors, is an unreliable guide to theophylline dosing, and monitoring of plasma concentrations is essential in order to optimise treatment.
Many patients experience gastrointestinal symptoms when their plasma concentration is within the therapeutic range, but minor adverse effects do not always precede major ones. Several of the adverse effects (nervousness, tachycardia, arrhythmias, and cardiorespiratory arrest) can be features of an acute attack of asthma, and it may be impossible to distinguish between features of the underlying disease and those attributable to theophylline toxicity without measuring the plasma theophylline concentration.
Is there a good relation between the plasma concentration and its therapeutic or toxic effects?
In experimental studies there is a linear relation between changes in forced expiratory volume in the first second (FEV1) and the logarithm of the plasma theophylline concentration over the range 17-1 10 pLmol/l. Oral theophylline In patients taking oral theophylline ideally a "'trough" (minimum steady state) plasma concentration should be measured. The time at which the "peak" plasma concentration occurs varies from 15 minutes after the dose (for elixirs) to two hours (for ordinary formulations) and four to six hours (for modified release formulations). This strictly limits the period during which the sample should be taken. As there is a circadian rhythm of theophylline metabolism, resulting in higher trough concentrations in the morning than later in the day, repeat samples for measurement of the trough concentration should be taken at the same time of day as previous samples to allow direct comparison of the results.
Given all these considerations the most practical strategy for routine monitoring is to tell the patient to take the morning dose on wakening and to measure the plasma theophylline concentration during the afternoon.
Modified release formulations may be taken at night, with measurement of the plasma concentration the next morning. In the period immediately after the second world war there existed a sense of social justice and a determination for mankind to control social and environmental factors that affected the health and quality of life. Abe Adelstein was a leading figure in the social medicine movement for over 40 years. He achieved this standing through his own research, through lasting changes in national vital statistics systems, and by enabling other researchers to address issues of import. His own research, including work on accident proneness and the incidence of mental illness in the community, as well as his studies of migrants and of social and economic differences in health, show his commitment to environmental explanations for patterns that he recorded.
His main contribution to the statistical infrastructure came through the use of record linkage-as in the national cancer registration scheme, the Office of Population Censuses and Surveys' longitudinal study, and the support that the OPCS provided to over 500 researchers wishing to follow up people in cohort studies. He also played a leading part in the development of the ninth revision of the International Classification of Diseases. The Medical Research Council's Epidemiological Monitoring Unit and Environmental Epidemiology Unit and the National Perinatal Epidemiology Unit were all established as a consequence of Abe's recognition of the value of subjecting routinely collected information to systematic in depth analysis.
Abe Adelstein was a private man; he achieved through collaboration, not conflict. His writing was simple and to the point. He was a wonderful mentor and genuinely wise. He prompted and questioned, without needing to demonstrate his knowledge and understanding. He recognised and overcame prejudices and barriers that had limited many of his medical contemporaries and predecessors. He was able to transcend class, disciplinary, and ethnic boundaries and enabled those with whom he had dealings to achieve their potential.
Above all, Abe Adelstein was a man of courage and determination with a remarkable will to live; despite all the health problems that affected him from the early 1 950s he never complained. He is survived by his wife, Cynthia, and a son and a daughter. 
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